Siam Oottamasathien, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Cationic Peptides | 6 | 2019 | 355 | 1.800 |
Why?
|
| Cystitis, Interstitial | 3 | 2019 | 66 | 1.640 |
Why?
|
| Glycosaminoglycans | 7 | 2021 | 606 | 1.340 |
Why?
|
| Urinary Bladder | 9 | 2018 | 1166 | 1.120 |
Why?
|
| Silk | 2 | 2021 | 90 | 0.820 |
Why?
|
| Cathelicidins | 6 | 2019 | 81 | 0.760 |
Why?
|
| Mast Cells | 2 | 2018 | 1428 | 0.620 |
Why?
|
| Elastin | 1 | 2019 | 301 | 0.590 |
Why?
|
| Urothelium | 5 | 2019 | 277 | 0.590 |
Why?
|
| Cystitis | 2 | 2013 | 96 | 0.520 |
Why?
|
| Olfactory Mucosa | 1 | 2015 | 99 | 0.490 |
Why?
|
| Spinal Dysraphism | 2 | 2014 | 174 | 0.470 |
Why?
|
| Penile Diseases | 2 | 2011 | 45 | 0.460 |
Why?
|
| Mesoderm | 2 | 2007 | 671 | 0.440 |
Why?
|
| Orchiectomy | 2 | 2007 | 470 | 0.430 |
Why?
|
| Polymers | 2 | 2021 | 1620 | 0.430 |
Why?
|
| Temperature | 1 | 2019 | 2221 | 0.410 |
Why?
|
| Testicular Neoplasms | 2 | 2007 | 800 | 0.360 |
Why?
|
| Sinusitis | 2 | 2016 | 992 | 0.340 |
Why?
|
| Proctitis | 2 | 2021 | 41 | 0.330 |
Why?
|
| Inflammation | 3 | 2018 | 10758 | 0.310 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 2218 | 0.300 |
Why?
|
| Rhinitis | 1 | 2015 | 747 | 0.290 |
Why?
|
| Hyaluronic Acid | 4 | 2018 | 482 | 0.290 |
Why?
|
| Pain | 2 | 2018 | 5066 | 0.260 |
Why?
|
| Wilms Tumor | 1 | 2007 | 376 | 0.230 |
Why?
|
| Replantation | 2 | 2018 | 145 | 0.220 |
Why?
|
| Embryonic Stem Cells | 2 | 2008 | 1262 | 0.210 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 18135 | 0.210 |
Why?
|
| Transplantation, Heterologous | 3 | 2008 | 2378 | 0.200 |
Why?
|
| Hydrogels | 4 | 2021 | 725 | 0.200 |
Why?
|
| Ureter | 2 | 2018 | 375 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 7 | 2019 | 22026 | 0.200 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2018 | 438 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 1956 | 0.170 |
Why?
|
| Mice, Nude | 5 | 2010 | 3605 | 0.160 |
Why?
|
| Crohn Disease | 1 | 2011 | 2275 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 1799 | 0.150 |
Why?
|
| Gels | 1 | 2019 | 419 | 0.150 |
Why?
|
| Enterotoxins | 1 | 2019 | 367 | 0.150 |
Why?
|
| Oligospermia | 1 | 2017 | 59 | 0.140 |
Why?
|
| Administration, Topical | 2 | 2016 | 696 | 0.140 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 88 | 0.140 |
Why?
|
| Mice | 14 | 2021 | 81212 | 0.140 |
Why?
|
| Receptors, LDL | 1 | 2019 | 491 | 0.140 |
Why?
|
| Dextrans | 1 | 2018 | 574 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 961 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1523 | 0.120 |
Why?
|
| Animals | 17 | 2021 | 167935 | 0.120 |
Why?
|
| Semen Analysis | 1 | 2017 | 232 | 0.120 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 1439 | 0.120 |
Why?
|
| Behavior, Animal | 2 | 2019 | 1861 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2015 | 18968 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2019 | 931 | 0.110 |
Why?
|
| Cell Differentiation | 3 | 2008 | 11481 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 2528 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2008 | 8159 | 0.110 |
Why?
|
| Testosterone | 1 | 2003 | 2469 | 0.100 |
Why?
|
| Bladder Exstrophy | 1 | 2013 | 106 | 0.100 |
Why?
|
| Urinary Calculi | 1 | 2012 | 91 | 0.100 |
Why?
|
| Urologic Diseases | 1 | 2014 | 247 | 0.100 |
Why?
|
| Restraint, Physical | 1 | 2013 | 186 | 0.100 |
Why?
|
| Administration, Intravesical | 1 | 2011 | 92 | 0.100 |
Why?
|
| Bandages | 1 | 2013 | 269 | 0.100 |
Why?
|
| Urethral Diseases | 1 | 2011 | 53 | 0.090 |
Why?
|
| Printing | 1 | 2010 | 46 | 0.090 |
Why?
|
| Micromanipulation | 1 | 2010 | 52 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 2 | 2008 | 64 | 0.090 |
Why?
|
| Prostatic Neoplasms | 2 | 2003 | 11341 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 2 | 2008 | 165 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 1705 | 0.080 |
Why?
|
| Biomimetic Materials | 1 | 2010 | 173 | 0.080 |
Why?
|
| Gelatin | 1 | 2010 | 221 | 0.080 |
Why?
|
| Cell Count | 1 | 2013 | 1838 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 11064 | 0.070 |
Why?
|
| Rats | 4 | 2008 | 23697 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 1549 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 1995 | 0.070 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2007 | 81 | 0.070 |
Why?
|
| Male | 20 | 2018 | 359427 | 0.070 |
Why?
|
| Mass Screening | 1 | 2003 | 5422 | 0.070 |
Why?
|
| Gold | 1 | 2010 | 485 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2013 | 1478 | 0.070 |
Why?
|
| Gonadoblastoma | 1 | 2006 | 14 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 222 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1399 | 0.070 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 401 | 0.070 |
Why?
|
| Extracellular Matrix | 2 | 2010 | 1726 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3806 | 0.060 |
Why?
|
| Cysts | 1 | 2011 | 683 | 0.060 |
Why?
|
| Infant | 5 | 2013 | 36032 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2214 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2010 | 708 | 0.060 |
Why?
|
| Turner Syndrome | 1 | 2006 | 130 | 0.060 |
Why?
|
| Cell Separation | 1 | 2010 | 1720 | 0.060 |
Why?
|
| Child | 9 | 2018 | 79759 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2018 | 2783 | 0.060 |
Why?
|
| Varicocele | 1 | 2004 | 78 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2007 | 361 | 0.060 |
Why?
|
| Infant, Newborn | 4 | 2013 | 26169 | 0.060 |
Why?
|
| Female | 14 | 2019 | 391024 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2015 | 3046 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2013 | 42036 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1663 | 0.050 |
Why?
|
| Proteins | 1 | 2017 | 6030 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2852 | 0.050 |
Why?
|
| Ethers | 1 | 2021 | 73 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2015 | 9287 | 0.040 |
Why?
|
| Humans | 21 | 2021 | 760276 | 0.040 |
Why?
|
| Tissue Engineering | 2 | 2008 | 1866 | 0.040 |
Why?
|
| Prostate | 1 | 2008 | 1793 | 0.040 |
Why?
|
| Transfection | 1 | 2007 | 5782 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 3731 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8551 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2006 | 5039 | 0.040 |
Why?
|
| Heparitin Sulfate | 1 | 2019 | 224 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 278 | 0.040 |
Why?
|
| Apoptosis | 1 | 2013 | 9497 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2003 | 1153 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 3601 | 0.040 |
Why?
|
| Retrospective Studies | 8 | 2018 | 80311 | 0.040 |
Why?
|
| Enema | 1 | 2017 | 141 | 0.030 |
Why?
|
| X-Rays | 1 | 2017 | 307 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3665 | 0.030 |
Why?
|
| Rheology | 1 | 2017 | 347 | 0.030 |
Why?
|
| Endocytosis | 1 | 2019 | 960 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 2016 | 265 | 0.030 |
Why?
|
| Adolescent | 5 | 2018 | 87749 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2019 | 1188 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 3105 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2004 | 2155 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2012 | 159 | 0.020 |
Why?
|
| Rectum | 1 | 2017 | 896 | 0.020 |
Why?
|
| Family Health | 1 | 2017 | 1258 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 9468 | 0.020 |
Why?
|
| Cell Death | 1 | 2016 | 1670 | 0.020 |
Why?
|
| Colon | 1 | 2019 | 1788 | 0.020 |
Why?
|
| Risk | 1 | 2003 | 9629 | 0.020 |
Why?
|
| Quality of Life | 2 | 2021 | 13301 | 0.020 |
Why?
|
| Cell Survival | 2 | 2010 | 5796 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 29640 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2019 | 3683 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2018 | 64968 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 4874 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 670 | 0.020 |
Why?
|
| Pregnancy | 2 | 2008 | 29727 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3023 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 1041 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 22066 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 685 | 0.020 |
Why?
|
| Protein Binding | 1 | 2019 | 9336 | 0.020 |
Why?
|
| Materials Testing | 1 | 2010 | 857 | 0.020 |
Why?
|
| Time Factors | 2 | 2010 | 40141 | 0.020 |
Why?
|
| Light | 1 | 2010 | 1343 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 23366 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 13629 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20483 | 0.010 |
Why?
|
| Ligation | 1 | 2004 | 448 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11708 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2018 | 15684 | 0.010 |
Why?
|
| Reoperation | 1 | 2010 | 4293 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 6965 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10529 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13315 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 6474 | 0.010 |
Why?
|
| Stem Cells | 1 | 2008 | 3525 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 24086 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 18416 | 0.010 |
Why?
|
| Mutation | 1 | 2019 | 29951 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10439 | 0.010 |
Why?
|
| Adult | 3 | 2017 | 219843 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41316 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 12100 | 0.000 |
Why?
|
| United States | 1 | 2012 | 72369 | 0.000 |
Why?
|
| Middle Aged | 1 | 2017 | 220179 | 0.000 |
Why?
|